Lupus Science & Medicine

Prevalence of falls in a pooled US cohort of adults with systemic lupus erythematosus: a nested cross-sectional study

Objective Epidemiologic data on falls in the population with systemic lupus erythematosus (SLE) remain sparse. We estimated ...
lupus.bmj

DIA proteomics of FFPE renal biopsies reveals two molecular subtypes of lupus nephritis and identifies APOL1 as candidate biomarker for stratification

Introduction Lupus nephritis (LN) exhibits substantial clinical and pathological heterogeneity. We aimed to define proteomics-based molecular subtypes of LN and identify candidate biomarkers for ...
lupus.bmj

Ultrasound detects subclinical joint inflammation in the hands and wrists of patients with systemic lupus erythematosus without musculoskeletal symptoms

Objectives To assess the prevalence and severity of ultrasonographic abnormalities of the hand and wrist of asymptomatic patients with systemic lupus erythematosus (SLE) and compare these findings ...
lupus.bmj

PO.6.134 Safety and tolerability of nipocalimab administered at different rates of intravenous infusion in healthy adults: a phase 1 placebo-controlled single-dose study

Purpose Systemic lupus erythematosus (SLE) is an IgG-mediated autoimmune disease. Nipocalimab, which is in clinical development for the treatment of SLE, targets the IgG binding site on neonatal Fc ...
lupus.bmj

P38 Descriptive analysis of patients positive for anti-PCNA antibodies

Background Proliferating cell nuclear antigen (PCNA) antibodies are a rare type of antinuclear antibodies (ANA), historically considered highly specific for systemic lupus erythematosus (SLE). Recent ...
lupus.bmj

98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)

Background XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgammaRIIb. Co-ligation of CD19 and FcgammaRIIb inhibits B lineage cells key to lupus pathogenesis. This ...
lupus.bmj

11 Managing haematologic manifestations in SLE

Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...
lupus.bmj

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
lupus.bmj

Programme: 13 th Annual Meeting of the Lupus Academy

6–8th September 2024Catch-up Content Available Online Until 31st December 2024http://www ...
lupus.bmj

13 Managing skin manifestations in SLE

Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...
lupus.bmj

12 Family planning and pregnancy in SLE

Case 1: A 35-year-old female with SLE and planning IVF pregnancy In October 2024 a 35-year-old female with systemic lupus erythematosus (SLE) was reviewed for planning of in vitro fertilization (IVF) ...
lupus.bmj

Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015

Objective To assess the economic burden of patients with SLE by disease severity in the USA 1 year before and after diagnosis. Methods Patients aged ≥18 years with a first SLE diagnosis (index date) ...